Apr. 15 at 1:43 PM
$LEXX Today’s update was pretty significant.
The GLP-1-A26-1 study is targeting SNAC alternatives—the current gold standard for absorption used by Novo Nordisk—Lexaria is positioning itself as a universal alternative for competitors like Eli Lilly.
• The "SNAC" Challenge: Hunting for a superior delivery method to SNAC allows Lexaria to bypass existing licensing gatekeepers, making them an essential partner for anyone entering the oral GLP-1 space.
• By quantifying drug delivery to the brain, Lexaria is addressing the neurochemical nature of weight loss. Superior brain penetration could mean higher efficacy at lower doses.
• Testing DHT-CBD alongside semaglutide targets a "super-formulation" for metabolic health and inflammation.
• Fully funded and set to dose in ~60 days, this study builds a long-term IP moat beyond the April 30th deadline.
This isn't just a study; it’s an IP land grab to ensure Lexaria becomes the "Intel Inside" for the next decade of GLP-1s.
$LLY $NVO $PFE
